Amneal Pharmaceuticals (AMRX) Financials: Revenue & Earnings

AMRX price $21.47 +0.03 +0.14%

Ticker
AMRX
Price
$21.47
Change
+0.03 +0.14%
Market cap ?
$6.86B
P/E ?
42.25
Forward P/E ?
20.90
Dividend yield ?
0.00%
Beta ?
1.22
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stocklytics score
50
Value
38
Quality
50
Growth
62

Stocklytics score rationale: value 38, quality 50, growth 62.

Financials

2016201720182019202020212022202320242025
1018225000103365400016629910001626373000199252300020936690002212304000239360700027939570003018760000

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct…

Fair value

AMRX fair value $28.47. Price $21.47. Price is 25% below fair value.

Above fair value, around its usual premium.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 255.48M. Growth 17.67%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 11.00% (beta 1.2). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 319.35M. Net debt 2.43B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare AMRX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-03—0.24—814.02M
2026-07-300.300.22796.20M768.21M
2026-05-070.270.17722.52M719.66M
2026-02-270.210.18814.32M807.35M
2025-10-300.170.13784.51M806.07M
2025-08-050.250.18724.51M768.60M
2025-05-020.210.15695.42M744.23M
2025-02-280.120.15730.52M723.09M
2024-11-080.160.13702.47M700.83M
2024-08-090.160.14701.78M658.14M
2024-05-030.140.09659.19M—
2024-03-010.140.07616.98M663.56M
2023-11-070.190.12620.04M634.23M
2023-08-040.190.10599.05M565.41M
2023-05-050.120.09557.54M537.31M
2023-03-020.230.21609.76M562.15M
2022-11-040.140.18545.56M—
2022-08-050.190.20559.36M—
2022-05-040.120.12497.63M535.91M
2022-03-020.180.19536.90M502.29M
2021-11-030.210.20528.59M544.49M
2021-08-090.250.18535.08M535.08M
2021-05-070.200.18493.11M438.32M
2021-02-260.140.13510.03M510.03M
2020-11-060.160.13519.29M519.29M
2020-08-060.130.10464.66M357.43M
2020-05-110.200.08498.53M411.29M
2020-02-260.080.05397.33M248.33M
2019-11-060.040.13378.28M1.32B
2019-08-050.090.15404.64M629.44M
2019-05-090.140.18446.12M573.58M
2019-02-280.330.26497.53M407.07M
2018-11-070.280.27476.49M476.50M
2018-08-090.240.23413.79M379.32M
2018-05-070.140.17275.19M334.17M
2018-03-010.110.11293.37M—
2017-11-090.230.20254.73M216.52M
2017-08-090.180.14259.87M185.62M
2017-05-100.110.131.03B—
2017-03-010.160.16298.58M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-17BUCHI J KEVINSell20.45K——
2026-09-11BUCHI J KEVINBuy20.45K$14.45295.43K
2026-09-11BUCHI J KEVINSell20.45K$14.45295.43K
2026-09-01BOYER ANDREW SSell80.00K——
2026-08-21BOYER ANDREW SSell152.43K——
2026-08-13Kiely JohnSell50.00K$17.64882.00K
2026-08-13Kiely JohnSell10.00K——
2026-08-12Shah NikitaSell146.40K$17.512.56M
2026-08-12Daly Jason B.Sell210.00K$17.403.65M
2026-08-11Daly Jason B.Sell6.61K$17.70117.05K
2026-08-11BUCHI J KEVINSell168.57K$17.182.90M
2026-08-10Patel Tushar BhikhubhaiBuy12.76M$375,000,000.004786.30T
2026-08-10Patel ChintuBuy6.38M$375,000,000.002393.15T
2026-08-10Patel GautamBuy283.63K$375,000,000.00106.36T
2026-08-10Patel Chirag K.Buy6.38M$375,000,000.002393.15T
2026-05-11Autor Deborah M.Sell34.82K$12.94450.56K
2026-05-07BUCHI J KEVINBuy34.82K——
2026-05-07BUCHI J KEVINSell34.82K——
2026-05-07Autor Deborah M.Buy34.82K——
2026-05-07Autor Deborah M.Sell34.82K——
2026-05-07George Jeffrey P.Buy34.82K——
2026-05-07George Jeffrey P.Sell34.82K——
2026-05-07Patel GautamBuy34.82K——
2026-05-07Patel GautamSell34.82K——
2026-05-07Kiely JohnBuy34.82K——
2026-05-07Kiely JohnSell34.82K——
2026-05-07Nark Ted CBuy34.82K——
2026-05-07Nark Ted CSell34.82K——
2026-05-07MEISTER PAUL MBuy48.75K——
2026-05-07MEISTER PAUL MSell48.75K——
2026-05-07Yanai ShlomoBuy34.82K——
2026-05-07Yanai ShlomoSell34.82K——
2026-05-06BUCHI J KEVINBuy19.82K——
2026-05-06Autor Deborah M.Buy19.82K——
2026-05-06George Jeffrey P.Buy19.82K——
2026-05-06Patel GautamBuy19.82K——
2026-05-06Kiely JohnBuy19.82K——
2026-05-06Nark Ted CBuy19.82K——
2026-05-06MEISTER PAUL MBuy30.84K——
2026-05-06Yanai ShlomoBuy19.82K——
2026-03-04Patel ChintuBuy92.59K——
2026-03-04Patel ChintuSell28.98K$13.30385.47K
2026-03-04Patel ChintuSell92.59K——
2026-03-04Patel Chirag K.Buy92.59K——
2026-03-04Patel Chirag K.Sell37.83K$13.30503.07K
2026-03-04Patel Chirag K.Sell92.59K——
2026-03-04Daly Jason B.Buy35.88K——
2026-03-04Daly Jason B.Sell15.58K$13.30207.21K
2026-03-04Daly Jason B.Sell35.88K——
2026-03-04Konidaris TasosBuy43.98K——
2026-03-04Konidaris TasosSell22.04K$13.30293.07K
2026-03-04Konidaris TasosSell49.98K——
2026-03-04BOYER ANDREW SBuy38.20K——
2026-03-04BOYER ANDREW SSell19.14K$13.30254.51K
2026-03-04BOYER ANDREW SSell38.20K——
2026-03-04Shah NikitaBuy35.88K——
2026-03-04Shah NikitaSell17.98K$13.30239.08K
2026-03-04Shah NikitaSell35.88K——
2026-03-03Patel ChintuBuy733.94K——
2026-03-03Patel ChintuSell315.88K$13.314.20M
2026-03-03Patel ChintuBuy59.93K——
2026-03-03Patel ChintuSell17.11K$13.31227.76K
2026-03-03Patel ChintuSell59.93K——
2026-03-03Patel ChintuSell733.94K——
2026-03-03Patel Chirag K.Buy733.94K——
2026-03-03Patel Chirag K.Sell297.54K$13.313.96M
2026-03-03Patel Chirag K.Buy59.93K——
2026-03-03Patel Chirag K.Sell15.62K$13.31207.85K
2026-03-03Patel Chirag K.Sell59.93K——
2026-03-03Patel Chirag K.Sell733.94K——
2026-03-03Daly Jason B.Buy305.81K——
2026-03-03Daly Jason B.Sell132.78K$13.311.77M
2026-03-03Daly Jason B.Sell24.26K——
2026-03-03Daly Jason B.Buy24.26K——
2026-03-03Daly Jason B.Buy38.23K——
2026-03-03Daly Jason B.Sell10.53K$13.31140.19K
2026-03-03Daly Jason B.Sell16.60K$13.31220.92K
2026-03-03Daly Jason B.Sell38.23K——
2026-03-03Daly Jason B.Buy22.64K——
2026-03-03Daly Jason B.Sell10.15K$13.31135.06K
2026-03-03Daly Jason B.Sell305.81K——
2026-03-03Daly Jason B.Sell22.64K——
2026-03-03Konidaris TasosBuy458.72K——
2026-03-03Konidaris TasosSell229.82K$13.313.06M
2026-03-03Konidaris TasosBuy28.54K——
2026-03-03Konidaris TasosBuy57.34K——
2026-03-03Konidaris TasosSell14.30K$13.31190.31K
2026-03-03Konidaris TasosSell24.25K$13.31322.78K
2026-03-03Konidaris TasosBuy45.29K——
2026-03-03Konidaris TasosSell16.18K$13.31215.38K
2026-03-03Konidaris TasosSell28.54K——
2026-03-03Konidaris TasosSell57.34K——
2026-03-03Konidaris TasosSell458.72K——
2026-03-03Konidaris TasosSell45.29K——
2026-03-03BOYER ANDREW SBuy397.55K——
2026-03-03BOYER ANDREW SSell199.18K$13.312.65M
2026-03-03BOYER ANDREW SBuy49.69K——
2026-03-03BOYER ANDREW SBuy24.26K——
2026-03-03BOYER ANDREW SSell12.15K$13.31161.77K
2026-03-03BOYER ANDREW SSell24.90K$13.31331.38K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 315, holders -5 vs prior quarter. Ownership 50.31%.

HolderSharesChangeChange %Value
BLACKROCK, INC.26.56M2.04M+8.33%459.79M
TPG GP A, LLC12.33M00.00%213.41M
VANGUARD PORTFOLIO MANAGEMENT LLC12.14M812.79K+7.18%210.10M
RUBRIC CAPITAL MANAGEMENT LP10.17M-868.93K-7.87%176.02M
VANGUARD CAPITAL MANAGEMENT LLC7.71M125.09K+1.65%133.46M
STATE STREET CORP7.36M562.27K+8.28%127.35M
DIMENSIONAL FUND ADVISORS LP5.79M103.68K+1.82%100.30M
GEODE CAPITAL MANAGEMENT, LLC5.14M593.40K+13.05%88.98M
MORGAN STANLEY4.11M-527.16K-11.37%71.14M
NEUBERGER BERMAN GROUP LLC3.89M204.90K+5.56%67.28M
INVESCO LTD.3.50M313.34K+9.83%60.62M
NUVEEN, LLC3.32M81.23K+2.50%57.55M
ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC3.30M745.96K+29.26%55.93M
GOLDMAN SACHS GROUP INC3.01M150.10K+5.24%52.17M
ASSENAGON ASSET MANAGEMENT S.A.2.45M-621.81K-20.27%42.33M
NANTAHALA CAPITAL MANAGEMENT, LLC2.27M-575.36K-20.23%39.27M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.2.15M2.15MNew37.17M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC2.15M-36.71K-1.68%37.17M
NORTHERN TRUST CORP1.91M208.79K+12.24%33.15M
ACADIAN ASSET MANAGEMENT LLC1.65M-281.64K-14.58%28.55M
AMERIPRISE FINANCIAL INC1.58M-283.33K-15.19%27.39M
WESTSHORE WEALTH, LLC1.37M-7.71K-0.56%23.65M
BLACKBARN CAPITAL PARTNERS LP1.30M-350.00K-21.21%22.50M
PENN CAPITAL MANAGEMENT COMPANY, LLC1.18M-14.90K-1.25%20.48M
VANGUARD FIDUCIARY TRUST CO1.17M15.26K+1.32%20.24M

Earnings and financials

Amneal Pharmaceuticals, Inc. (AMRX) trades at $21.47, with a market cap of $6.86B and a trailing P/E of 42.25. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
1018225000103365400016629910001626373000199252300020936690002212304000239360700027939570003018760000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Amneal Pharmaceuticals (AMRX) Financials: Revenue & Earnings

AMRX$21.47+0.03 +0.14%

$6.86B

Market Cap

42.25

P/E

20.90

Forward P/E

50

Score

Price History